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Objectives.The authors reported a retrospective study onmyxoid liposarcomas (MLs), evaluating factors that may influence overall
survival (OS), local recurrence-free survival (LRFS), metastasis-free survival (MFS), and analyzing themetastatic pattern.Methods.
148MLs were analyzed.The sites of metastases were investigated. Results.Margins (𝑝 = 0.002), grading (𝑝 = 0,0479), andmetastasis
(𝑝 < 0,0001) were significant risk factors affecting overall survival (OS). Type of presentation (𝑝 = 0.0243), grading (𝑝 = 0,0055),
margin (𝑝 = 0.0001), and local recurrence (0.0437) were risk factors on metastasis-free survival (MFS). Authors did not observe
statistically significant risk factors for local recurrence-free survival (LRFS) and reported 55% extrapulmonary metastases and
45% pulmonary metastases. Conclusion.Margins, grading, presentation, local recurrence, and metastasis were prognostic factors.
Extrapulmonary metastases were more frequent in myxoid liposarcoma.
1. Introduction
Liposarcoma is one of the most common sarcomas found in
adults [1, 2] and it can be defined as a mesenchymal malig-
nancy characterized by adipocyte differentiation. Differ-
ent forms of liposarcoma are described: atypical lipomatous
tumor/well differentiated (ALT/WD), dedifferentiated lipo-
sarcoma (DDLs), myxoid liposarcoma (MLs), and pleomor-
phic liposarcoma (PLs) [2–5].
Myxoid liposarcoma is the secondmost common subtype
(MLs). It accounts for 15–20% of liposarcomas and represents
about 5% of all soft tissue sarcomas in adults. Histologically
MLs show a continuous spectrum of lesions with low grade
forms and others poorly differentiated round cells forms [2].
MLs presents the recurrent translocation 𝑡(12;16)(q13;p11)
that results in FUS-DDIT3 gene fusion, present in >95% of
cases. In the remaining cases, a variant 𝑡(12;22)(q13;q12) is
present in whichDDIT3 (also known as CHOP) fuses instead
with EWSR1, a gene that is highly related to FUS. They have
a peak incidence in the fourth and fifth decade of life, in
particular on the lower extremities and buttock [2, 6, 7].
Another feature that distinguishes theMLs thanother lipo-
sarcomas is the tendency to metastasize in unusual regions
correlated to worst prognosis and more precisely where fat
tissue is present as the trunk, extremities, bone, retroperito-
neal site, the chest wall, the pleura, and pericardium [8–11].
Factors affecting the prognosis inMLs include age at diag-
nosis, tumor size, tumor grade, depth of tumor, and surgical
margins [12–16]. Differentiation, necrosis,mitotic rate, prolif-
eration index (MIB-1, Ki-67 immunostain), and overexpres-
sion of P53 represent morphological prognostic factors in
MLs [12, 13, 16]. Surgical excision with or without radiation
therapy is the treatment of choice in the localized MLs.
Chemotherapy is generally reserved for patients with high
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risk disease such as high grade, deep sited tumor, tumor size
> 5 cm, and positive surgical margins.
The aim of our retrospective study was to evaluate factors
that may influence overall survival (OS), local recurrence-
free survival (LRFS), and metastasis-free survival (MFS) in
a series of 148 patients withMLs treated in a single center. We
analyzed the metastatic pattern of MLs and the propensity to
give extrapulmonary metastases to define a proper clinic and
imaging pathway.
2. Materials and Methods
We retrospectively reviewed histological and clinical records
of 148 patients treated between 1994 and 2015. The mean age
was 49 years (16–82), 142 (96%) liposarcomas localized in the
limbs and 6 (4%) in the trunk.
All data collected included patient characteristics (age,
gender), tumor characteristics (site, size, clinical symptoms,
stage, and histology), the diagnostic and therapeutic proce-
dures (type of biopsy, type of surgery, margins, neoadjuvant,
and adjuvant therapy), and clinical outcome.
The data were obtained from the patient’s medical
records. Local recurrence and distant metastasis after treat-
ment were recorded. Each patient underwent anamnestic
collection of his medical history, physical examination, and
routine blood tests; electrocardiogram and chest X-ray were
obtained. Considering that X-ray or CT were not useful to
identify the features and the edges of the primary tumor,MRI
was performed in most patients. MRI was particularly useful
in defining certain characteristics such as homogeneity,
necrosis, hemorrhagic areas, the local spread of the disease
(size), and tumor stages. Chest CT scan, bone scan, or PET
(from 2009) was performed preoperatively.
At diagnosis, all patients had a localized soft tissue
sarcoma in absence of metastases.
Histological diagnosis was confirmed by open incisional
biopsy, ultrasound needle biopsy, or previous inadvertent
excision performed at other centers. All available histologic
slides were reviewed and tumors were graded according to
WHO 2013 classification of soft tissue sarcomas [2]. High
grade (“round cell”) areas were characterized by solid sheets
of back-to-back primitive round cells with a high nuclear to
cytoplasmic ratio, with no intervening myxoid stroma [2]. If
these areas represented more than 5% of the tumor, this was
considered as high grade. FISH for DDIT3 was performed in
dubious forms of high gradeMLs for the differential diagnosis
with other soft tissue sarcomas.
Following the initial work-up the surgical approach was
the main treatment that attempts to get wide margins. When
the tumor was adjacent to critical structures such as nerves,
blood vessels, or bones, a planned marginal surgery has been
accepted.
Radiotherapy (RT) in preoperative or postoperative set-
ting was performed in patients with high grade disease or
tumor size > 5 cm and deep sited tumors or in case of close/
positive margins.
External beam radiotherapywas deliveredwith 6–10MeV
photons; Gtv (Gross Tumor Volume) was obtained contour-
ing the surgical bed or the gross tumor in case of preoperative
RTonT1weightedMRI images, CTV (clinical targetVolume)
derived from an expansion of 1.5 cm radially, and 4 cm
longitudinally from theGTV, andfinally 0.5 cmwere added to
the CTV to obtain the PTV (planning target volume). There
was a total dose of 50Gy and 60Gy in preoperative and
postoperative setting, respectively.
A standard fraction schedule was used: 2Gy per fraction,
5 days a week.
Chemotherapywas performed in patients withmore than
two of these unfavourable prognostic factors: high grade
disease, tumor size > 5 cm, deep sited tumors, and positive
surgical margins. Chemotherapy consisted of three or five
cycles of epirubicin (60mg/m2, Days 1-2) and ifosfamide
(3 g/m2, Days 1–3) administered every 21 days.
The patients were followed every 3 months for the first
2 years, every 4 months during 3rd year, every 6 months for
4th-5th years, and annually from 6th to 10th year.
The statistical analysis was performed with MedCalc
software version 16.8.4. Values of 𝑝 ≤ 0,05 were considered
statistically significant. All variables were analyzed for their
impact on overall survival, local recurrence-free survival, and
metastasis-free survival with a follow-up of 5 and 10 years.
In univariate analysis of the overall survival estimates, local
recurrence-free survival and metastasis-free survival were
calculated according to the method of Kaplan-Meier.
The comparison of survival curves calculated was per-
formed by the log-rank test media. The hazard ratios and
confidence intervals (95%) were calculated using the Cox
hazard test.
3. Results
Our data included 103 (70%) primitive liposarcomas, 26
(17%) local recurrences of primitive liposarcoma, and 19
(13%) radicalizations of liposarcoma treated elsewhere. The
locations were the lower extremities in 129 (87%) cases, the
upper limb in 13 (9%) cases, and trunk in 6 (4%) cases.
Specifically 5 (3%) liposarcomas were localized at themuscles
of the shoulder, 3 at the arm, 5 at the elbow and distal to the
elbow, 10 in pelvic muscles, 76 in the thigh, and 43 in the knee
and distal to the knee. Six liposarcomas were localized in the
muscle of the trunk. The preoperative MRI showed size > to
10 cm in 47 (32%) patients, between 5 and 10 cm in 67 (45%)
patients, and <5 cm in 34 (23%) patients (Table 1).
100 (68%) tumors were classified low grade (<5% round
cells) and 48 (32%) high grade (>5% round cells).
At the final histology 105 (71%) MLs were treated with
radical or wide surgery, 41 (28%)withmarginal surgery, and 2
(1%) with intralesional excision. The preoperative radiother-
apy was performed in 41 MLs (14 cases with size > 10 cm,
18 cases between 5 and 10 cm, and 9 cases with dimensions
< 5); the postoperative radiotherapy was performed in 63
patients (14 < 5 cm, 32 between 5 and 10 cm, and 17 > 10 cm)
of which 17 patients had marginal or compromised margins
at histological examination and in 30 patients with high grade
MLs (Table 2).
Chemotherapy was administered in 45MLs patients with
aggressive histological type, 25 neoadjuvant chemotherapy,
and 29 postoperative chemotherapy (Table 2).
International Journal of Surgical Oncology 3
Table 1: Main features.
Characteristics N∘ %
Patients 148 100
Presentation:
Primary 103 70
Local recurrence 26 17
Radicalization 19 13
Grading:
Low grade (<5% round cell) 100 68
High grade (>5% round cell) 48 32
Site:
Lower limb 129 87
Upper limb 13 9
Trunk 6 4
Size:
>10 cm 47 32
5–10 cm 67 45
<5 cm 34 23
Table 2: Surgical margins, radiotherapy, chemotherapy, local recur-
rence, and metastasis.
Wide/radical Marginal Intralesional
Margin 105 41 2
Preoperative Postoperative
Radiotherapy 41 63
Chemotherapy Neoadjuvant Adjuvant
25 29
Local
recurrence 15 (10%)
8 (wide/radical
surgery),
7 (marginal
surgery)
Metastasis 20 (14%) 7 (wide/radicalsurgery),
15 (marginal
surgery)
Site metastasis
55% extrapulmonary, 45% pulmonary (9 lung, 2
liver, 5 spine, 1 peritoneum, 1 kidney, 1 dorsal soft
tissue, and 1 chest wall)
The average follow-up was 73 months (range 6–257); 76
patients had a greater than 5-year follow-up.
4. Local Recurrence
We observed 15 (10%) local recurrences with mean free
interval of 29 months (range 1–81 months).
EightMLs treatedwith radical orwide excision developed
local recurrence, 3 with size > 10 cm, 3 with size > 5 cm, and
only 2 with sizes < 5 cm. A patient with local recurrence
underwent amputation for involvement of neurovascular
bundle, six patients were treated with excision, and one
patient was lost.
SevenMLs treatedwithmarginal excision developed local
recurrence, 4 with size > 10 cm, 2 with size > 5 cm, and 1 with
size < 5 cm. Five local recurrences were treated with excision
and 2 with amputation for involvement of neurovascular
bundle.
No patients treated with intralesional surgery developed
local recurrence.
We did not observe statistically significant risk factors for
the local recurrence-free survival (LRFS) (Table 4).
LRFS was 89% at 5 years and 86% at 10 years.
5. Metastasis
Twenty MLs (14%), 7 MLs treated with wide resection and
13 with marginal surgery, developed metastases. The sites
of metastases were 9 lung, 2 liver, 5 spine, 1 chest wall, 1
peritoneum, 1 kidney, and 1 dorsal soft tissue
One patient treatedwith intralesional excision died after 3
months, while one patient withMLs (size> 5 cm) treatedwith
intralesional excision and postoperative radiation therapy
has not developed local recurrence and metastases after 142
months of follow-up.
Margins (𝑝 = 0.0001), grading (𝑝 = 0, 0055) (Figure 4),
type of presentation (𝑝 = 0, 0243) (Figure 6), and local recur-
rence (𝑝 = 0, 0437) (Figure 5) are risk factors on metastasis-
free survival (MFS) (Table 5).
FiveMLs with local recurrences developed distantmetas-
tases.
MFS was 85% at 5 years and 82% 10 years.
6. Overall Survival
Statistical analysis indicates margins (𝑝 = 0.002) (Figure 1)
and grading (𝑝 = 0.0479) (Figure 2) are a risk factor on over-
all survival (OS) and the appearance of metastases is a highly
significant Factor (𝑝 < 0.0001) (Figure 3) (Table 3).
OS was 90% at 5 years and 85%, respectively, at 10 years.
7. Multivariate Analysis
In multivariate analysis for MFS only the margins (𝑝 =
0.0004) was statistically significant, unlike the type of pre-
sentation (𝑝 = 0.0906) and the event local recurrence (𝑝 =
0.0821). In the multivariate analysis for OS only metastasis
was statistically significant (𝑝 < 0,0001), unlike margins (𝑝 =
0,1039).
8. Discussion
The study reports the outcome in terms of recurrence-free
survival, metastasis-free survival, and overall survival, in a
series of 148 patients with MLs diagnosed and treated in a
single center over the last 21 years.
Limb salvage with wide margin is the main treatment
in soft tissue sarcomas surgery. Amputation is reserved only
when neurovascular bundle is involved, in cases of severe
tissue impairment caused by radiotherapy and finally in
unsolvable postsurgical infectious complications. Our results
showed that surgical margins had an impact on metastasis-
free survival (MFS) and overall survival (OS) while local re-
currence-free survival (LRFS) was not correlated with mar-
gins. Inadequate surgical margins increased the risk to devel-
op metastasis (𝑝 = 0,0001) affecting negatively OS (𝑝 =
0.002), according to other reported series [12, 13, 17, 18].
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Table 3: Statistical analysis indicates that margins (𝑝 = 0.002),
grading (𝑝 = 0,0479), and the metastasis (𝑝 < 0,001) are risk factors
on overall survival (OS).
Overall survival
Variables Survival at5 years (%)
Survival at
10 years
(%)
𝑝 value
(LR test)
Site
Upper limb 92 73
0,6215Lower limb 89 86
Trunk 100 100
Size
<5 cm 81 81
0,42685–10 cm 95 88
>10 cm 89 89
Grading, round cell (RC)
Low (RC < 5%) 95 87 0,0479
High (RC > 5%) 80 80
Margin
Wide/radical 96 92
0,002Marginal 76 66
Intralesional 50 50
Presentation
Primitive 91 91
0,0755Local Recurrence 78 72
Radicalization 100 80
LR
No 92 86 0,2821
Yes 76 76
RT
No 90 90 0,7921
Yes 90 85
CHT
No 94 87 0,1766
Yes 83 83
Metastases
No 98 98
<0,0001
Yes 42 22
Surgical excision should be carefully planned by experienced
surgeons considering the areas in proximity of vascular
structures, nerves, and bone [19, 20]. The treatment of MLs
in facilities not specialized in cancer care is an important
risk factor for local recurrence. Lemeur reported 23% of
local recurrence in a series with six patients treated ini-
tially in nonspecialized centers, including 4 managed with
intralesional excision; only one had a preoperative MRI and
no patient underwent preoperative biopsy [14], stressing the
importance of surgical planning in agreement with other
authors [12, 13, 17, 18]. Engstro¨m et al. reported a 47%
recurrence for tumors operated in nonspecialized setting
[20]. Chandrasekhar et al. reported 59% of local recurrences
Table 4: Statistical analysis shows no significant risk factors for the
local recurrence-free survival (LRFS).
Local recurrence-free survival
Variables Survival at5 years (%)
Survival at
10 years
(%)
𝑝 value
(LR test)
Site
Upper limb 91 91
0,5852Lower limb 89 85
Trunk 67 67
Size
<5 cm 97 82
0,28835–10 cm 91 91
>10 cm 77 77
Grading, round cell (RC)
Low (RC < 5%) 89 87 0,4824
High (RC > 5%) 87 83
Margin
Wide/radical 92 88
0,1085Marginal 78 78
Intralesional 100 100
Presentation
Primitive 87 85
0,2061Local recurrence 86 78
Radicalization 100 100
RT
No 94 81 0,9303
Yes 88 86
CHT
No 90 88 0,2035
Yes 85 81
on 363 cases treated inadequately [21]. This finding is also
confirmed by our data: local recurrence of tumors treated
in nonspecialized center in cancer care had a higher risk
to develop distant metastases (𝑝 = 0.0243) (Table 5). In our
series we observed 15 recurrences (10.1%) in 8 MLs treated
with wide and in 7 with marginal surgery. Local recurrence
rate was lower compared to 14% observed by Mayo Clinic
group [22] and 21.7% at 5 years observed by Fiore et al. [13].
The low rate of local recurrence in our series can be explained
by the fact that 70.2% of patients received prior postoperative
radiotherapy. Accordingly Guadagnolo et al. observed 3% of
local recurrences in 127 MLs treated with preoperative or
postoperative radiation therapy [23]. It was postulated that
the effectiveness of radiation therapy inmyxoid liposarcomas
is related to radiosensitivity of the delicate blood supply,
characteristic of this tumor [24]. Hannibal et al. observed a
very low rate of local recurrence (4%) in patients with purely
myxoid liposarcoma (low grade) treated with wide margins.
For these patients, the role of radiation therapy appears more
questionable [17].
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Figure 1: Margins represent a significant risk factor (𝑝 = 0,002) in
overall survival (OS).
In several series, the proportion of round cell and the
histologic grade represent a prognostic factor influencing
the overall survival. This was confirmed by our data: overall
survival was 95% at 5 years and 87% at 10 years for MLs with
round cells < 5% and 80% at 5 years and 80% at 10 years for
MLs with round cells > 5%. Fiore et al. reported 93% overall
survival for patientswithMLs including round cell forms [13].
Haniball et al. reported a dramatically worse 5-year survival
of 58% [17] highlighting that round cell > 5% increases the
risk of local recurrence by more than 3 times and concluding
that this subgroup of patients should primarily be treated
by radiotherapy and chemotherapy. Dalal found an overall
survival rate of 92% at 5 years for patients with round cells
< 5% compared to 74% of patients with round cells > 5% [25].
The role of chemotherapy in patients with soft tissue
sarcomas has been extensively investigated [26] and several
studies highlighted the potential sensitivity of liposarcoma to
chemotherapy [23, 26–28]. Given the high risk of developing
metastases, high gradeMLs are suitable to chemotherapy and
to new experimental protocols.
Tumoral site (upper limb, lower limb, and trunk) did not
result in a significant risk factor, even though the few number
of patients with trunk localization could have hampered
statistical significance.
Tumor size is generally considered a prognostic factor for
soft tissue sarcomas. Several studies have reported that larger
tumors > 10 cm are associated with a poor prognosis [19, 20,
22, 29]. Size did not represent a significant prognostic factors
in our series.
Local recurrence in our series was associated with an
increased risk to develop metastases (𝑝 = 0.0437) and death
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Figure 2: Grading is a significant risk factor (𝑝 = 0,0479) in overall
survival (OS).
due to cancer. Five patients who developed early local recur-
rence, simultaneously or subsequently developed metastases
and all died. Early local recurrence is generally considered a
poor prognostic indicator [19].
According to other authors, we observed a high rate of ex-
trapulmonary metastases in MLs. Metastatic spread involved
the lungs in 45% of cases and extrapulmonary sites in 55%
of cases. Estourgie reported extrapulmonary metastases in
55% of patients with metastastic disease and recommended
to follow up the patients with regular CT scan of the
abdomen and pelvis [11]. Guadagnolo et al. reported 78% of
metastasis localized in extrapulmonary sites, of which 48%
in retroperitoneal space [23]. Several other authors found
a high rate of extrapulmonary metastases in MLs, ranging
from 41% to 77% [10, 12, 13, 18]. From these reports, common
sites of metastases were the retroperitoneum, the abdominal
and thoracic wall, and the abdominal cavity. Schwab et al.
reported the skeleton as the most frequent site of metastasis,
identifying 8 patients with skeletal lesions in a population of
184 MLs (4.3%). In this series, more than half of metastases
(56%) were skeletal lesions, in particular localized to the
spine, 70% in the absence of pulmonary localizations [8].
The reason of the tendency of MLs to metastatic spread
in extrapulmonary sites is not clear. Ogose et al. speculated
that the abundance of fat tissue in metastatic sites, such as the
subcutaneous tissue, retroperitoneum, bone marrow, and the
epidural space might favour the metastatic seeding [30].
An important issue is to assess whether extrapulmonary
lesions are metastatic lesions or different sites of metachro-
nous disease. Smith et al., analyzing the genomic rearrange-
ment of TLS, CHOP, or EWS in six patients, confirmed the
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Figure 3: Metastasis is a high significant risk factor (𝑝 < 0,0001) in
overall survival (OS).
monoclonal origin of myxoid multifocal liposarcoma. They
concluded that this unusual clinical phenomenonmay repre-
sent a pattern of hematogenous metastatic spreading to other
soft tissue sites, with cells unable to colonize the lungs [31].
Some authors highlighted an influence in the prognosis of
some factors such as adipophilin, a well-known adipogenesis
marker that appears early in the differentiation process [32],
perhaps suggesting that MLs differentiate beyond the initial
stage before the interruption of complete adipocyte matura-
tion. Hoffmann et al. observed a significantly higher level of
adipophilin in high grade than in low grade MLs, suggesting
a role in the progression of the disease [33]. Other factors
which are particularly expressed in MLs are the adipogenesis
regulator PPAR𝛾 [34] and CXCR4 (chemokine receptor),
overexpressed in high grade tumors [35]. Overexpression of
p53 in MLs [12] correlated with a poor chemotherapeutic re-
sponse.The PDGFR-𝛽expression in the MLs was foundmost
frequently in metastatic forms (especially to bone) than in
localized lesions [36].
An issue is what kind of imaging to use during follow-up
of MLs for an early detection of extrapulmonary metastases.
Some authors reported the failure of both PET scan and bone
scan to detect metastases of myxoid liposarcoma [8]. Other
options are total body CT and MRI who remain the most
reliable screening tools. In particular, total body MRI may
reveal the presence of extrapulmonary metastases at an early
stage, when they are still not symptomatic, without radiation
exposure.
9. Conclusion
Our study confirmed that inadequate surgical margins in
MLs represent a significant risk factor to develop metastases
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Figure 4: Grading is a significant risk factor (𝑝 = 0,0055) in metas-
tasis-free survival (MFS).
(𝑝 = 0.001) with consequent negative influence on overall
survival (𝑝 = 0.002). Surgical excision of MLs should be per-
formed in specialized centers by experienced sarcoma sur-
geons. Inadequate primary treatment more frequently leads
to local recurrence and metastasis (𝑝 = 0.0243). Local recur-
rences increase the risk to develop metastases (𝑝 = 0.0437)
andmetastatic event has a highly significant impact on overall
survival (𝑝 < 0.001). Grading affects OS (𝑝 = 0,0479) and
MFS (𝑝 = 0,0055). Amultidisciplinary approach toMLs is re-
commended, considering combining surgery to radiation
therapy and/or chemotherapy in selected cases. The aware-
ness of the high incidence of extrapulmonary metastases,
especially in fat-rich areas, should lead to clinical and imaging
investigation such as total bodyMRI, aiming to an early diag-
nosis.
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8 International Journal of Surgical Oncology
Table 5: Statistical analysis indicates margins (𝑝 = 0.0001), grading
(0,0055), type of presentation (𝑝 = 0.0243), and local recurrence
(0.0437) as risk factors on metastasis-free survival (MFS).
Metastases-free survival
Variables Survival at5 years (%)
Survival at
10 years
(%)
𝑝 value
(LR test)
Site
Upper limb 72 72
0,4542Lower limb 86 82
Trunk 100 100
Size
<5 cm 86 86 0,2716
5–10 cm 88 86
>10 cm 80 70
Grading, round cell (RC)
Low (RC < 5%) 91 88 0,0055
High (RC > 5%) 72 68
Margin
Wide/radical 94 88
0,0001Marginal 62 62
Intralesional 100 100
Presentation
Primitive 90 86
0,0243Local recurrence 65 65
Radicalization 93 84
LR
No 88 84 0,0437
Yes 65 65
RT
No 82 82 0,9645
Yes 86 82
CHT
No 87 84 0,2363
Yes 81 76
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